The Continuum Team

Comprised of world-class scientists, chemists, and biotechnology experts within the fields of aging and metabolic disease, each team member brings unique expertise and seasoned experience to the table, ensuring the strength and merit of the Continuum mission.

Webster Santos

Webster Santos, Ph.D.

Webster Santos is co-founder of Continuum Biosciences, and is currently Professor of Chemistry and the Cliff and Agnes Lilly faculty fellow of Drug Discovery at Virginia Tech. As the inventor of over 16 patents, he has drug discovery expertise in targeting HIV-1 related RNAs, sphingosine-1-phosphate pathway, and mitochondrial uncoupling. He serves on the editorial boards of Medicinal Research Reviews and Current Topics in Medicinal Chemistry, and is the recipient of numerous awards, including the Innovators Award and an endowed Blackwood Faculty Fellowship at Virginia Tech. He received his BS and PhD at the University of Virginia, which was followed by an NIH postdoctoral fellowship in the department of chemistry and chemical biology at Harvard University.


Kyle Hoehn, Ph.D.

Kyle Hoehn is Co-founder of Continuum Biosciences. Dr. Hoehn is a metabolic biochemist and physiologist conducting cutting-edge research on obesity and its related disorders including diabetes and obesity-related cancers. His work is focused on altering metabolism to treat disease and delay aging. Dr. Hoehn received a PhD in Biochemistry from Colorado State University and completed postdoctoral training at the Garvan Institute of Medical Research in Sydney. Dr. Hoehn is currently the Chief Scientific Advisor at Continuum Biosciences and holds professorship appointments at both the University of New South Wales and the University of Virginia.


Simon Tucker Ph.D.

Dr. Simon Tucker is CEO of Continuum Biosciences, Inc. and brings decades of experience in pharmaceutical research and development and management. He previously worked at GD Searle, USA, helping make key discoveries leading to the development of a treatment for HIV infection. He was later Vice President of Research at Biota Pharmaceuticals (now Vaxart), where he was responsible for their entire intellectual property and research portfolio. In 2015, he founded and was CEO of the successful contract research organization, 360biolabs. Dr. Tucker has a BS in Biochemistry from the University of Sussex and a PhD from the University of Reading.


Lawrence Gozlan

Lawrence Gozlan is Chairman of the board of Continuum Biosciences and the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively in life sciences. With 18 years of experience in investing and banking, Lawrence has expertise in all areas of investment management and deep roots in the scientific and biotech communities. Prior to Scientia Lawrence was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte. Lawrence currently serves as a Director on the Board of Nohla Therapeutics, Prana Biotechnology (NASDAQ: PRAN) and Ausbiotech, Australia’s biotechnology industry association. He holds a BS with Honors in immunology from the University of Melbourne.


John Amatruda, M.D.

Dr. John Amatruda is President of Life Laboratories, a division of Life Biosciences, and a member of Life's Scientific Advisory Board. Throughout his 26-year career in drug research and development, Dr. Amatruda has produced drugs that treat diabetes, obesity, cardiovascular disease and more. In addition to tenures as a professor at Yale University School of Medicine and The University of Rochester School of Medicine, he also co-founded the biotech company CohBar, served on numerous scientific advisory panels and Boards of Directors and was a Vice President at Bayer Corp and a Senior Vice President at Merck Pharmaceuticals. A prolific author, Dr. Amatruda has published over 150 papers, abstracts, reviews and book chapters, primarily on diabetes and cardiovascular disease. Dr. Amatruda received a BA from Yale University, an MD from the Medical College of Wisconsin and completed clinical training in Medicine and fellowship in Endocrinology and Metabolism at the Johns Hopkins Hospital.


Tristan Edwards

Tristan Edwards is a board member of Continuum Biosciences and is also Co-Founder and the CEO of Life Biosciences. Additionally, he sits on the board of Animal Biosciences, Senolytic Therapeutics and Jumpstart Fertility. Tristan brings extensive global financial capital markets, regulatory compliance, and fiduciary oversight experience to the group, following a 16-year investment career spanning leading financial organizations across Australia, London, HK and Singapore. Having recognized the opportunity to leverage this experience in an entrepreneurial environment, he has subsequently moved to pursue his passion for helping create a scalable platform for financing and enabling the world’s best scientists and thought leaders to create change. Tristan’s professional background has been in senior investment roles at leading financial groups such as Goldman Sachs, Brevan Howard, Trafalgar Capital and Mosaic Asset Management. He started his career with the Australian Commonwealth Department of Finance. Tristan has a degree in Commerce from the University of Tasmania, and held the CFA, CMT and CPA designations.


David Sinclair, Ph.D., A.O.

David A. Sinclair Ph.D., A.O. is a board member of Continuum Biosciences and Co-Founder at Life Biosciences. He is a tenured professor in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for the Biology of Aging Research. Dr. Sinclair is regarded as one of the world’s leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the process. He has co-founded multiple biotechnology and genomics companies working on aging, neurological, metabolic, infectious and rare diseases. Dr. Sinclair’s work has been featured in five books, two documentary movies, on CBS 60 Minutes, in Morgan Freeman’s “Through the Wormhole” and more. He has received more than 35 awards for his medical research, innovation, and teaching. In 2014, he was named as TIME’s “100 Most Influential People in the World”, TIME’s “50 Most Influential People in Health Care” in 2018 and was appointed an Officer of the Order of Australia. He serves on the non-profit boards of the American Federation for Aging Research and the Sanford Lorraine Cross Award.